Dr Anguraj Sadanandam completed his MSc (5 years integrated) in Life Sciences from Bharathidasan University (Trichy, India) during which he did his external trainings in bioinformatics at Jawaharlal Nehru University (New Delhi, India). Later, he worked very briefly as a Research Fellow at International Center for Genetic Engineering and Biotechnology (New Delhi, India).
Dr Sadanandam obtained his PhD in Pathology and Microbiology with specialty in Bioinformatics from the University of Nebraska Medical Center, Omaha, Nebraska under Prof. Rakesh K. Singh, where he combined both wet-lab and bioinformatics to identify and characterize metastatic biomarkers in pancreatic adenocarcinoma (PDA). He also developed a publicly available database, mammalian cell adhesion molecule (MCAM).
As a postdoctoral fellow with Prof Joe Gray at Lawrence Berkeley National Lab (LBNL, for about 2 years), he gained significant experience analysing different types of molecular data from tumours produced using high-throughput technologies, such as microarrays and massively parallel sequencing (MPS). There, he developed PDA subtypes with prognostic and predictive significance. In addition, he reclassified breast cancer cell lines into subtypes that match the existing patient tumour subtypes and predicted gene expression subtype- and DNA copy number change-specific therapy by screening 77 different approved and experimental therapeutic compounds. During this time, he developed a hypothesis and later showed that multiple epithelial organ-type tumours have consensus subtypes with therapeutic significance using tissue-independent gene expression profiles.
Dr Sadanandam further continued his postdoctoral fellowship (for less than 2 years) under the mentorship of Prof Douglas Hanahan at the Swiss Federal Institute of Lausanne (EPFL) and co-mentorship of Prof Joe Gray. Later, he joined Swiss Institute of Bioinformatics (SIB), Lausanne as a Senior Research Scientist in Dr Olivier Michielin group, however, continued his collaboration as a Guest Scientist in Prof. Douglas Hanahan lab at EPFL. During these positions, he identified novel subtypes and correlated them to therapeutic responses using genetically engineered mouse (GEM) and transplanted mouse models by performing preclinical therapeutic trial design especially for colorectal cancer (CRC) and pancreatic neuroendocrine tumors (PNETs). He also identified fusion genes and currently characterizing their functions in breast cancer cell lines. In particular, these positions gave him a practical understanding of how to validate hypotheses generated from high-throughput data in whole organism biological systems.
Dr Sadanandam joined the ICR in September 2013 as a Team Leader and currently applying his multidisciplinary skills to integrated science of systems biology to identify and test precise therapies for different subtypes of cancers using wet-lab and bioinformatics.